Navigation Links
Biomarker predicts response to cancer treatment
Date:5/21/2012

Leuven, 21 mei 2012 - VIB researcher Diether Lambrechts, associated with KU Leuven, has discovered a biomarker that might potentially predict which patients will benefit more from treatment with bevacizumab (Avastin). If validated, this discovery could be an important step towards personalized medicine and patient-tailored use of this important cancer drug.

Diether Lambrechts (VIB KU Leuven) said "in two large clinical studies with patients with advanced stages of pancreas and kidney cancer a variant in the DNA was discovered that identified patients who did not respond well to the prescribed course of bevacizumab. Further research in the lab showed that this variant, or biomarker, was responsible for increasing the production of a certain protein that is hypothesized to neutralize the effect of bevacizumab in these patients. If this marker would be clinically validated, the marker could be used to distinguish patients that would benefit from the drug from those that would not, and spare them a futile therapy with possible side effects."

Biomarkers for targeted treatments

Oncologists want to use treatments that target the particular cancer. Every cancer is characterized by a specific set of proteins that is responsible for the abnormal behavior of the tumor. Therapies aimed at blocking these proteins can significantly extend the life of cancer patients, provided that they receive the drug that is right for them. Cancers with a different set of proteins will not respond to a therapy that does not target those proteins. That is why developing biomarkers for all targeted therapies is so important.

An antibody as cancer drug

Eric Van Cutsem (UZ Leuven) explains that "Bevacizumab is a targeted therapy but there is no clinically validated biomarker yet. In clinical practice, patients in the advanced stages of colon, renal, lung and breast cancer are already being given bevacizumab in addition to their conventional (chemo)therapy. The monoclonal antibody bevacizumab neutralizes the wild growth of blood vessels triggered by the tumor in support of its aggressive growth. Currently studies are under way to determine whether bevacizumab could also be used for other cancers."

DNA variants

Diether Lambrechts and Bart Claes (VIB/KU Leuven) looked at blood samples from cancer patients participating in 2 clinical studies and receiving bevacizumab or a placebo in addition to standard treatment. They subsequently looked for genetic variations in the DNA that could predict specifically how long patients survived in the group treated with bevacizumab but not in the placebo group. This is how they came upon a variant that showed predictive value for treatment with bevacizumab. These findings are a nice result of all efforts being done to identify a biomarker for bevacizumab.

More research necessary

The results of this study are well advanced but not final. Additional studies are needed to further validate the findings scientifically. However, it is a promising start for the personalized use of this drug. And it should be noted here that biomarkers like these do not only benefit patients but, given the high price of new cancer drugs, will help keep healthcare affordable.


'/>"/>
Contact: Sooike Stoops
sooike.stoops@vib.be
32-924-46611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related medicine news :

1. New biomarker test predicts arthritis at much earlier stage, MU researchers say
2. Early biomarker for pancreatic cancer identified
3. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
4. Biomarkers can reveal IBS
5. SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples
6. Biomarker identified in relation to drug response in refractory urothelial cancer
7. Panel of serum biomarkers may reduce number of lung biopsies needed
8. Biomarkers identify acute kidney injury in emergency patients
9. Genetic sequencing could help match patients with biomarker-driven cancer trials, treatments
10. Metabolic syndrome biomarkers predict lung function impairment after exposure to WTC dust
11. Mass. General Cancer Center and Vall dHebron Institute of Oncology biomarker alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Tenn. (PRWEB) , ... April 28, 2017 , ... ... system, today announced an alliance with B. Braun Medical Inc. , a leader ... role in patient care with as many as 90 percent of hospital patients receiving ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... deodorant. On the heels of Thinksport’s award-winning sunscreen they’ve used the same scientific ... actually works! , Countless deodorants flood the aisles that contain harmful chemicals that ...
(Date:4/27/2017)... ... April 27, 2017 , ... Goodcents Deli Fresh Subs announced a franchise expansion ... this year. , The first new location will open at the corner of ... 84th and Northern Lights Drive this fall. And the third location is in the ...
(Date:4/26/2017)... ... April 26, 2017 , ... Jump Technologies, Inc., an innovative ... has completed a round of funding to accelerate its growth strategies. The $3.5 ... Capital is a growth equity firm focused on investments in healthcare and technology ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... describes the adoption of e-prescribing as measured in Part D Medicare data. The ... prescriptions to pharmacies, either using e-prescribing, faxes or paper. The PaPR (pronounced ...
Breaking Medicine News(10 mins):
(Date:4/25/2017)... , April 25, 2017 Endo International plc (NASDAQ: ... May 9, 2017. Members of its senior management team will host ... at 8:30 a.m. ET. The dial-in number to ... International (678) 509-7598, and the passcode is 6086379. Please dial in ... A replay of the call will be available ...
(Date:4/20/2017)... April 20, 2017  Vivify Health, the pioneer and ... been awarded a very significant patent for the advancement ... continual care via digital health.  This landmark patent provides ... and further secures Vivify,s position as the leader in ... was the first company to apply consumer mobile devices, ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
Breaking Medicine Technology: